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Abstract
In order to obtain a comprehensive form of mathematical models describing nonlinear phenomena such as HIV infection process
and AIDS disease progression, it is efﬁcient to introduce a general class of time-dependent evolution equations in such a way that
the associated nonlinear operator is decomposed into the sum of a differential operator and a perturbation which is nonlinear in
general and also satisﬁes no global continuity condition. An attempt is then made to combine the implicit approach (usually adapted
for convective diffusion operators) and explicit approach (more suited to treat continuous-type operators representing various
physiological interactions), resulting in a semi-implicit product formula. Decomposing the operators in this way and considering
their individual properties, it is seen that approximation–solvability of the original model is veriﬁed under suitable conditions. Once
appropriate terms are formulated to describe treatment by antiretroviral therapy, the time-dependence of the reaction terms appears,
and such product formula is useful for generating approximate numerical solutions to the governing equations.With this knowledge,
a continuous model for HIV disease progression is formulated and physiological interpretations are provided. The abstract theory is
then applied to show existence of unique solutions to the continuous model describing the behavior of the HIV virus in the human
body and its reaction to treatment by antiretroviral therapy. The product formula suggests appropriate discrete models describing
the dynamics of host pathogen interactions with HIV1 and is applied to perform numerical simulations based on the model of the
HIV infection process and disease progression. Finally, the results of our numerical simulations are visualized and it is observed
that our results agree with medical and physiological aspects.
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1. HIV infection process
HIV infection process and AIDS disease progression. Determination of CD4+T cell counts and measurement of the
levels of HIV RNA in serum or plasma provide effective methods for determining prognosis and monitoring response
to antiretroviral therapy. While the CD4+T cell count provides information on the current immunological status of
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the patient, the HIV RNA level predicts what will happen to the CD4+T cell count in the near future. Measurement
of changes in HIV RNA levels over time has been used to show levels of virus and rates of disease progression, the
rates of viral turnover, the relationship between immune system activation and viral replication, and the period for
development of drug resistance.
HIV RNA measurement is inﬂuenced by the state of activation of the immune system and may ﬂuctuate in the
setting of secondary infections or immunization. The CD4+T cell count is generally recognized as the best indicator
of the immediate state of immunologic competence of the patient with HIV infection. Patients with HIV infection are
suggested to have CD4+T cell measurements performed at the time of diagnosis and every 3–6 months. According to
most guidelines, a CD4+T cell count less than 500 per l is an indication for consideration of initiating antiretroviral
therapy, and a decline in CD4+T cell count of greater than 25% is an indicating a change of therapy. The clinical
consequences ofHIV infection encompass a spectrum ranging froman acute syndromeassociatedwith primary infection
to a prolonged asymptomatic state to advanced disease.
It is best to regard HIV disease as the process from the beginning at the time primary infection to progressing
through various stages. Active virus replication and progressive immunologic impairment occur throughout the course
of HIV infection in most patients. With the exception of long-term nonprogressors, HIV untreated patients progress
even during the clinically latent stage. Lymphoid tissues are the major sites for the establishment and propagation of
HIV infection. For practical reasons, most studies on the pathogenesis of HIV infection have focused on peripheral
blood mononuclear cells. However, lymphocytes in the peripheral blood represent only a few percent of the total body
lymphocyte pool and so may not always accurately reﬂect the status of the entire immune system; most of lymphocytes
in the human body reside in lymphoid organs. Virus replication occurs mainly in lymphoid tissue and not in blood; the
level of plasma viremia reﬂects virus production in lymphoid tissue.
The events associated with primary HIV infection may be critical determinants of the subsequent course of HIV
disease. In particular, the dissemination of virus to lymphoid organs is a major factor of the establishment of a chronic
and persistent infection. It appears that the initial level of plasma viremia in primary HIV infection does not neces-
sarily determine the rate of disease progression. However, the set point of the level of steady state plasma viremia
after approximately 1 year seems to correlate with the rapidity of disease progression. Once infection has been es-
tablished the virus is virtually never cleared completely from the body. Rather, a chronic infection develops that
persists with varying degrees of virus replication for a median of approximately 10 years before the patient becomes
clinically ill.
While the mechanisms of evasion from immune system control are not completely clear, several theories have been
proposed as playing a role in this phenomenon. HIV virus have an extreme ability to mutate, but this occurs mostly
after the establishment of chronic infection and contributes to the maintenance of chronicity. During primary HIV
infection and the transition to established chronic infection, both activated HIV-speciﬁc CTLs and CTL precursors are
preferentially segregated in the peripheral blood, where very little active virus replication takes places, rather than in
the lymphoid tissue. HIV virus succeed in establishing a state of chronic infection with a variable degree of persistent
virus replication. In most cases, during this period the patient makes the clinical transition from acute primary infection
to a relatively prolonged state of clinical latency. It has been demonstrated that there exists in virtually all HIV-infected
individuals a pool of latently infected resting CD4+T cells, and that this pool of cells likely serves as at least one
component of the persistent reservoir of virus. They are established during the course of primary HIV infection. Despite
the suppression of plasma viremia to below detectable levels (less than 50 copies of HIV RNA per milliliter) by potent
combinations of several antiretroviral drugs for as long as 3 years, this pool of latently infected cells persists and can
give rise to replication-competent virus.
Treatment with effective combinations of antiretroviral drugs has extended the median time. Currently, individ-
ual patients are considered to be long-term survivors if they remain alive for 10–15 years after initial infection.
Some of these individuals have CD4+T cell counts that have decreased to less than 200 per l but have remained
stable at that level for years. The mechanisms of this stabilization are not entirely understood but may relate to
effective antiretroviral therapy and prophylaxis against opportunistic infection. In addition, in some individual, the
virus may either have been less virulent initially or may have mutated to a less virulent form under the inﬂuence of
antiretroviral therapy.
Antiretroviral therapy for HIV infection. Ongoing HIV replication causes to the damage of immune system and
progression to AIDS disease, and so a goal of therapy is the maximal suppression of viral replication. Combination
antiretroviral therapy is the foundation of management of patients infected with HIV virus. The most effective strategy
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of antiretroviral therapy should involve the simultaneous initiation of combinations of effective anti-HIV drugs with
which the patients have not been previously treated and should not be cross-resistant with antiretroviral drugs that
patients have already received. The antiretroviral drugs employed in combination regimens needs to be used according
to optimal schedules and dosages. Any decisions on antiretroviral therapy need to have a long-term impact on future
options for the patient. At present, many of the most important questions related to the treatment of HIV disease do not
have deﬁnite answers. Among them are the questions of when therapy should be started, what the best initial regimen
is, when a given regimen should be changed, and what it should be changed to when a change is made. In an effort
to facilitate this decision process, the United States Department of Health and Human Services has published a series
of frequently updated guidelines including the “Principles of Therapy of HIV Infection”, “Guidelines for the Use of
Antiretroviral Agents in HIV-Infected Adults and Adolescent”, and “Guidelines for the Prevention of Opportunistic
Infections in Persons Infected with HIV”.
Currently, licensed drugs for the treatment of HIV infection fall into twomain categories as those that inhibit the viral
reverse transcriptase enzymeand those that inhibit the viral protease enzyme.There are numerous drug–drug interactions
that need to be taken into consideration when using these agents. There are drugs among FDA-approved reverse
transcriptase inhibitors include the nucleoside and the nonnucleoside analogues should not be used as monotherapy for
HIV infection. Physicians ensure that the patient should also be on additional antiretroviral medication. The reverse
transcriptase inhibitors block the HIV replication cycle at the point of RNA-dependent DNA synthesis in the step of
reverse transcription. While the nonnucleoside reverse transcriptase inhibitors are quite selective for the HIV-1 reverse
transcriptase, the nucleoside analogues inhibit a variety of DNA polymerization reaction in addition to those of the
HIV-1 reverse transcriptase. For this reason, serious side effects are more common with the nucleoside analogues and
include mitochondrial damage that can lead to hepatic steatosis and lactic acidosis as well as peripheral neuropathy
and pancreatitis.
The introduction of the HIV-1 protease inhibitors to the therapy is important. When used as part of initial regimens
in combination with reverse transcriptase inhibitors, these agents have been shown to be capable of suppressing levels
of HIV replication to under 50 copies per milliliter in the majority of patients for a minimum of 3 years. As in the case
of reverse transcriptase inhibitors, resistance to protease inhibitors can develop rapidly in the setting of monotherapy,
and thus these agents should be used as part of combination regimens of therapy. Treatment decisions are based on
the fact that one is dealing with a chronic infection. While early therapy is generally the rule in infectious disease,
immediate treatment of every HIV-infected individual when diagnosis are made may not give the best results, and
decisions in therapy takes into account the balance between risks and beneﬁts.At present, a reasonable course of action
is to initiate antiretroviral therapy in anyone with the acute HIV syndrome; patients with symptomatic disease; patients
with asymptomatic disease with CD4+T cell counts less than 500 perml or with greater than 20,000 copies of HIV
RNA per microliter. Once the decision has been made to initiate therapy, the health care providers decide which drugs
to use as the ﬁrst regimen. The decision regarding choice of drugs not only will affect the immediate response to therapy
but also will have implications regarding options for future therapy regimens. The initial regimen is usually the most
effective as the virus has not developed signiﬁcant resistance.
The two options for initial therapy which are most commonly used today are two different three-drug regimens. The
ﬁrst regimen utilizes two nucleoside analogues and a protease inhibitor. The second regimen utilizes two nucleoside
analogues and a nonnucleoside reverse transcriptase inhibitor. There are no clear data at present on which to base
distinctions between these two approaches. Following the initiation of therapy a 1 log reduction in plasma HIV RNA
levels within 1–2 months and eventually a decline in plasma HIV RNA levels to less than 50 copies per milliliter should
be expected. During the same time, there should be a rise in the CD4+T cell counts of 100–150 perml. Other reasons
for a change in therapy include a persistently declining CD4+T cell count, clinical deterioration, or drug toxicity.
As in the case of initiating therapy, changing therapy may have a lasting impact on future options of therapy. When
changing therapy because of clinical progression or worsening laboratory parameters, it is recommended to attempt to
provide a regimen with at least two new drugs. For the patient in whom a change is made for reasons of drug toxicity,
a replacement of one drug is suggested. Plasma HIV RNA levels and CD4+T lymphocyte counts are to be monitored
every 3–4 months during therapy, and more frequently if one is considering a change in regimen or immediately
following a change in regimen. HIV resistance proﬁles should improve outcomes of therapy in patients failing their
current antiretroviral regimen. Rates of disease progression differ among individuals, and treatment decisions are to be
individualized in accordance with plasma HIV levels and CD4+T cell counts. We here refer to [1] for details.
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2. A HIV infection model
In view of the discussions in Section 1, we here make an attempt to formulate a mathematical model for describing
the dynamics of host pathogen interaction with HIV1 and disease progression. The model given here is based on those
treated in [3,8]. Once an appropriate form of treatment by antiretroviral therapy were introduced, then time-dependence
of the reaction terms would appear in the model. Moreover, from the point of view of the antiretroviral therapy, it is
preferable to formulate a sequence of mathematical models which are associated with the change of therapies. Let
m denote nonnegative integers m = 0, 1, 2, . . . and represent the mth stage of applied therapies. The stage of m = 0
is associated with the stage of primary infection. In order to formulate a mathematical model which describes the
dynamics of HIV disease progression under the mth therapy, we employ the following parameters:
The symbols u,wsm,wrm, uˆsm and uˆrm denote, respectively, the population of healthyCD4+T cells, that ofCD4+T
cells infected with virus which are all sensitive to the mth therapy, CD4+T cells infected with virus which are partly or
totally resistant to the mth therapy, CD4+T cells infected with only drug-sensitive virus in the resting phase under the
mth therapy, and CD4+T cells infected with drug-resistant virus in the resting phase under the mth therapy. Moreover,
vsm and vrm stand for the population of drug-sensitive virus and that of drug-resistant virus under the mth therapy. In
particular, vs0 stands for the original population of virus which ﬁrst invaded into the human body.Also, vrm are generated
from vsm through mutation with mutation rate m under the mth therapy, although most of vrm may be changed to a
part of vsm+1 under the (m + 1)th therapy which is supposed to be more effective than the mth therapy.
In the case that, at some time t = tm+1, the mth therapy is judged to become ineffective for suppressing the disease
progression and extensive mutation of virus, the therapy is changed to a new therapy called the (m+1)th therapy which
is supposed to be more effective against the disease. In this case it is crucial to formulate suitable initial conditions at
time t = tm+1 for the (m+ 1)th therapy. For this purpose we suppose that two (drug sensitivity) rates m and m can be
speciﬁed in the following way: sensitive virus under the mth therapy remain to be sensitive under the (m+1)th therapy
with the rate of m. Also, resistant virus under the mth therapy remain to be resistant under the (m + 1)th therapy with
the rate of m. Hence, the initial conditions at time t = tm+1 take the following forms:
vsm+1(tm+1) = (1 − m)vrm(tm+1) + mvsm(tm+1),
vrm+1(tm+1) = mvrm(tm+1) + (1 − m)vsm(tm+1).
(1) The population dynamics of healthy CD4+T cells may be described by the following equation:
(/t)u = du∇2u − vf · ∇u
+ S + p1,m(Vtotal,m) − u
− [1msmvsm + rmvrm ]u
− [1msm + rm ]u − [R,sm + R,rm ]u.
In the above equation, the ﬁrst two terms on the right-hand side represent diffusion and transportation along the (blood
or lymph) ﬂow ﬁeld vf . The second three terms mean natural supply, supply due to immune response depending upon
the total population
Vtotal,m := vsm + vrm ,
and natural mortality, respectively. Also, the third two terms stand for infection of u with drug-sensitive and resistant
virus with infection rates 1msm and rm , respectively. Further, the fourth two terms express infection of u with
drug-sensitive and resistant virus generated from uˆsm and uˆrm with infection rates sm and rm , respectively.
Finally, the ﬁfth two terms represent transition from wsm and wrm to uˆsm and uˆrm in the resting phase with transition
rates R,sm and R,rm , respectively. The transition rates R,sm and R,rm should be measured, although it should be
mentioned that these rates are linked with the population of uˆsm and uˆrm in the following way: It is reasonable to
assume that the transition rates R,sm and R,rm are products of pure transition rates R,sm and R,rm and infection rates
in such a way that
R,sm = R,smsm and R,rm = R,rmrm .
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We employ the saturation functions
pk,m(	) = p∗k,m	/(ck,m + 	) for 	0 and k = 1, . . . , 4,
p5,m(	) = p∗5,m	/(c5,m + 	) for 	
; =0 for 	<
,
and the treatment function
1m(x, t) = exp(−d1(x)t), t0, x ∈ ,
which is a rapidly decaying positive function on [0,∞) for each x ∈ .
(2) Secondly, the population dynamics of drug-sensitive virus may be described through the equation:
(/t)vsm = dvs∇2vsm − vf · ∇vsm
+ (1 − m)p3,m(Vtotal,m)vsm
+ 1msmvsm + 2mp4,m(Vtotal,m)vsm − εm(t)vsm .
In the above equation, the ﬁrst two terms on the right-hand side represent diffusion and advection along the ﬂow ﬁeld vf
generated by the circulation system. The second term means that drug-sensitiveness is remained under the mth therapy.
Also, the third term stands for the restriction (by 1m and 2m) of regeneration of drug-sensitive virus. Finally, the
fourth term represents the decrease effect due to the immune system under the mth therapy.
Here the function εm(t) represents a decay phenomenon induced by the immune system. In the normal state, the
count ofCD4+T lymphocytes is about 1000 per l. In six weeks after the primary infection, it goes down to 500 per l.
Then the immune system is activated and the amount recovers to 800 per l, although it decreases about 50 through
100 counts per ml every year and CD4+T cell count turns out to decline below the threshold 250 per l. This process
takes place on the primary stage of infection. Under antiretroviral therapy, the immune system is again activated to
recover the population of CD4+T cells. Therefore the graph of function εm(t) may be illustrated as follows:
Also, we have employed two treatment functions of the forms:
1m(x, t) = exp(−d1m(x)t), 2m(x, t) = max{exp(−d2m(x)t), d3m(x)},
where d1m, d2m and d3m are bounded positive measurable functions.
(3) Thirdly, the population dynamics of drug-resistant virus may be described by the equation below:
(/t)vrm = dvr∇2vrm − vf · ∇vrm
+ p3,m(Vtotal,m)[mvsm + vrm ]
+ rmvrm − εm(t)vrm .
In the above equation, the ﬁrst two terms on the right-hand side represent diffusion and advection along the ﬂow ﬁeld vf
generated by the (blood and lymph) circulation system. The second two terms mean generation of drug-resistant virus
and regeneration of drug-resistant virus due to mutation, respectively. Finally, the third two terms stand for regeneration
of drug-resistant virus and immune response of the immune system under the mth therapy.
Here the function εm(t) is supposed to be same as in (2). Since all the virus involved in this equation are drug-
resistant under the mth therapy, treatment functions of the forms 1m and 2m as introduced in (2) are not included in
this dynamics. It is understood that the above equation may be linked with wsm in the sense that
vsm = Kamp, sm · wsm, vrm = Kamp, rm · wrm ,
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where Kamp, sm and Kamp, rm mean the ampliﬁcation rates of vsm and vrm in CD4+T cells, respectively. It is known
that if an HIV virus individual vsm or vrm invades into a CD4+T cell, then over 500 HIV copies are generated from it.
(4) Fourthly, the following equation may be employed as a governing equation to describe the population dynamics
of drug-sensitive infected cells:
(/t)wsm = dws∇2wsm − vf · ∇wsm
− p2,m(Vtotal,m)wsm − mwsm
+ 1msmvsmu + 1msmu − R,smwsm .
In the above equation, the ﬁrst two terms on the right-hand side represent diffusion and advection along the ﬂow
ﬁeld vf . The second two terms mean immune response and natural mortality, respectively. Also, the ﬁfth term stands
for the restriction of drug-sensitive infection and infection with drug-sensitive virus generated from uˆsm , respectively.
Finally, the last term represents transition from wrm to latently infected cells uˆrm . Here 1m is the treatment function as
introduced in (2) and the equation is coupled with uˆsm through the infection rate:
sm = sm · Kamp, sm · act,sm · uˆsm
for some weight sm ∈ [0, 1], an ampliﬁcation rate Kamp, sm and an activation rate act,sm .(5) Fifthly, the population dynamics of drug-resistant infected cells may be described by the following equation:
(/t)wrm = dwr∇2wrm − vf · ∇wrm
− p2,m(Vtotal,m)wrm − ˆmwrm
+ rmvrmu + rmu − R,rmwrm .
In the above equation, the ﬁrst two terms on the right-hand side represent diffusion and advection along the ﬂow ﬁeld
vf . The second two terms mean immune response and natural mortality, respectively. Also, the ﬁfth term stands for
resistant infection and infection with resistant virus generated from uˆrm , respectively. Finally, the last term represents
transition from wrm to latently infected cells uˆrm . This equation is coupled with uˆrm through the infection rate:
rm = rm · Kamp, rm · act,rm · uˆrm, rm ∈ [0, 1]
for some weight rm ∈ [0, 1], an ampliﬁcation rate Kamp, rm and an activation rate act,rm .(6) The population dynamics of drug-sensitive latently infected cells may be described by the following equation:
(/t)uˆsm = duˆs∇2uˆsm − vf · ∇uˆsm
+ R,smwsm − ¯muˆsm
− 1mact,muˆsm − p2,m(Vtotal,m)act,sm uˆsm .
In the above equation, the ﬁrst two terms on the right-hand side represent diffusion and advection along the ﬂow ﬁeld
vf . The second two terms mean transition fromwsm to uˆsm and natural mortality, respectively.Also, the ﬁfth term stands
for activation of latently infected cells and treatment, respectively. Finally, the last term represents immune response
to the activated uˆsm . The rate R,sm is the transition rate in the mth stage and ¯m means the mortality rate which is
understood to be small, since uˆsm tends to stay at speciﬁc parts of the lymphatic system for a comparatively long period
such as several months or even a few years.
(7) The following equationmay be employed as a governing equation for the population dynamics of latently infected
drug-resistant cells:
(/t)uˆrm = duˆr∇2uˆrm − vf · ∇uˆrm
+ R,rmwrm − ¯muˆrm
− p2,m(Vtotal,m)act,rm uˆrm .
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In the above equation, the ﬁrst two terms on the right-hand side represent diffusion and advection along the ﬂow ﬁeld
vf . The second two terms mean transition from wrm to uˆrm and natural mortality, respectively. Finally, the last term
stands for immune response to the activated uˆrm .
In themathematicalmodel asmentioned above,wehave employed the following rates and coefﬁcients: the coefﬁcients
sm and rm denote the rates of infection ofCD4
+T cellswith virus sensitive and resistant to themth therapy, respectively.
R,sm and R,rm mean the rates of infection of CD4
+T cells in the resting phase with drug-sensitive and drug-resistant
virus under the mth therapy; act,sm and act,rm represent the rates of activation of uˆsm and uˆrm which are transitional to
wsm and wrm , respectively; Kamp, sm and Kamp, rm denote the rates of ampliﬁcation of vsm and vrm generated in the
infected cells wsm and wrm , respectively. The symbols sm , sm , rm and rm mean the natural mortality rates of wsm ,
uˆsm ,wrm and uˆrm , respectively. Finally, m stands for the mutation rate under the mth therapy.
3. A time-dependent product formula
Stable solvability of the mathematical model introduced in the previous section is veriﬁed by applying the so-called
semi-implicit product formula. The numerical solvability can also be discussed through a similar approach. See [2,7]
for detailed arguments. By virtue of the abstract theory given below, we may treat parabolic evolution systems of the
form (RDS) below. This will form the basis for studying mathematical models formulated as in the previous section.
Here we assume that the reaction terms together satisfy the assumptions of our theory, and we focus our attention
on the diffusion and advection terms that make up an operator A. For simplicity, we employ a single functional to
describe the secondary bornological structure and justiﬁcation for this particular choice is presented when we discuss
the application to our HIV infection model.
Let  be a bounded domain in Rn with sufﬁciently smooth boundary . We write  to represent the Laplace
operator on  under homogeneous Neumann boundary conditions, and we write ∇ for the spatial gradient operator.
A general reaction diffusion system takes the following form:
⎧⎨
⎩




(un)t = dnun − bn · ∇un +n(t, u1, . . . , un),
(RDS)
in the product Banach space X = (Lp())n for p>n, where the norm ‖ · ‖X is given by
‖(z1, . . . , zn)‖X = (‖z1‖pp + · · · + ‖zn‖pp)1/p.
The functions bi are all assumed to be of the class C1(¯;Rn) so that the Gauss divergence theorem may be applied. In
many applications, we seek locally bounded nonnegative solutions to (RDS). We deﬁne
D = (L∞+ ())n, L∞+ () = {v ∈ L∞() : v(x) = 0, a.e. x}
and three functionals
0(v) = IndD(v), 1(v) = ‖v1‖∞, 2(v) = max1 in ‖vi‖∞
for v = (vi)ni=1, where IndD(·) is the indicator function of D, namely,
IndD(v) = 0 for v ∈ D and IndD(v) = +∞ for v /∈D.











d1u1 − b1 · ∇u1
...












1(t, u1, . . . , un)
...




Given that all of the coefﬁcients bi are in the class C1(¯;Rn), there exists some uniform constant of quasidissipativity
 for the operator A. Furthermore, resolvent operators (I − hA)−1, which are deﬁned everywhere on the space X, are
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nonexpansive with respect to j . Namely,
j ((I − hA)−1u)(1 − 0h)−1(j (u) + j h) for h ∈ (0, h0) and j = 0, 1, 2 (1)
for some constants 00, h0 ∈ (0, 1/0) and j 0, j = 0, 1, 2. Application of Theorem 2 stated below and a
regularity theorem for the parabolic system (RDS) imply the following:
Theorem 1. There exist unique strong solutions to the system (RDS) for all initial data in D, where D ≡ {u ∈ X :
j (u)<∞, j = 0, 1, 2}.
We now consider an abstract evolution equation in X, allowing for the case in which time-dependent components
exist, and introduce a new product formula to deal with such situations. The abstract form of such equations is given
below:
u′(t) = (A + B(t))u(t), t > 0, u(0) = v ∈ D, (EE)
where solutions are considered under a certain growth condition. Under certain assumptions on the operators A and
B(t) in the evolution equation (EE), it is ﬁrstly shown that the product formula can be deﬁned for an appropriate
class, denoted D, of initial data, and that it satisﬁes a stability condition with respect to a secondary bornological-type
structure. With this knowledge, convergence to a generalized solution can be shown. The time-dependent evolution
system (EE) is understood to be a universal form of mathematical models describing nonlinear phenomena such as
HIV infection and disease progression.
The growth condition we employ in this argument is written as
For all > 0 there exists K ∈ B such that u(t) ∈ K for t ∈ [0, ], (GC)
and the precise meaning of this is explained below.





i=0 on X is given to represent characteristic quantitative parameters for the nonlinear phenomena under
consideration which represent total population of cells, that of virus and so on. Deﬁne sets
Di, = {v ∈ X : i (v)} (2)
for i = 0, 1, . . . , p and > 0. For each i = 0, 1, . . . , p, Di is deﬁned to be the effective domain of i , and D the
intersection of all Dis, i.e., the set of points at which each i takes a ﬁnite value:
Di = ∪
>0
Di,, i = 0, 1, . . . , p, and D =
p∩
i=0Di . (3)
We say that a set K ⊂ X belongs to the classB if and only if there exists a sequence {i
}p
i=0 of nonnegative constants
such that i (v)i for i = 0, 1, . . . , p and v ∈ K . The set D is understood to be a class of admissible initial data. The
family B forms the basis of a bornology, which is an abstraction of the concept of a family of bounded sets.
In order to specify the time-dependence of the operatorB(t), we introduce a class of functions (s, t) of two variables
on the triangle 0s t, > 0,which representmoduli of time-dependence.A function  : [0, ]×[0, ] → [0,+∞)
is said to be a modulus of time-dependence if : (i)  is bounded and upper semicontinuous on [0, ] × [0, ], (ii)
(s, t)= (t, s) and (s, s)= 0 in the sense that lim sup↓0{(s, t) : |s − t |} = 0. We here denote by T the family
of all moduli of time-dependence on [0, ] × [0, ].
The assumptions placed on the operators A and B(t) are stated as follows:
(H1) For any > 0 there exist b0 > 0 and 0 > 0 such that
0((I + B(t))v)(1 + b0)(0(v) + c0) (4)
for t ∈ [0, ], 0< < 0 and v ∈ D0. For any > 0, i with 1 ip, and any sequence {j 0}i−1j=0, there exists
bi0 such that
i ((I + B(t))v)(1 + bi)(i (v) + ci)
for  ∈ (0, 0), 0< < 0, v ∈ D0,0 ∩ · · · ∩ Di−1,i−1 ∩ Di, (t ∈ [0, ]. (5)
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(H2) For any > 0 and any K ∈ B, there exist L,K > 0 and B,K ∈T such that
‖B(s)u1 − B(t)u2‖L,K‖u1 − u2‖ + B,K(t, s) for s, t ∈ [0, ], u1,u2 ∈ K .
(H3) There is a constant 1 ∈ (0, 0) and the resolvent (I − A)−1 is deﬁned on D for  ∈ (0, 1). Moreover, for
each i ∈ {0, 1, . . . , p} there exist constants ˆi0 and ˆi such that
i ((I − A)−1v)(1 − ˆi )−1(i (v) + ˆi )
for  ∈ (0, 1), t ∈ [0, ] and v ∈ D.
(H4) For all > 0 and K ∈ B, there exists ,K0 such that
[Av − Aw, v − w]−,K‖v − w‖ + A,K(t, s) for v,w ∈ D(A) ∩ K .
Here [v,w]− denotes the lower semi-inner product on X. See [4] for details. Under the four assumptions stated above,
it is possible to deﬁne a sequence {uhi }[/h]i=0 through the following semi-implicit scheme:
uh0 = v, uhi = (I − hAih)−1(I + hB(i−1)h)uhi−1, i = 1, . . . , [/h], (6)
provided that h ∈ (0, h0) and h01. It is then shown that given > 0,K ∈ B and v ∈ K , there exists K ∈ B such
that the elements uhi generated by the (6) all satisfy
uhi ∈ K for h ∈ (0, h0) and i with ih ∈ [0, ].
It follows that the error terms fhi satisfy
fhi = h−1[uhi − uhi−1] − (Aih + Bih)uhi , i = 1, . . . , [/h], (7)
lim
h↓0 max1 i [/h] ‖f
h





i ‖ = 0, (8)
allowing us to apply the results of Kobayasi et al. [4] to obtain the following.
Theorem 2 (Convergence Theorem). Under the hypotheses (H1) through (H4), there exists a generalized solution u(t)
to (EE) satisfying the associated growth condition (GC) and uhi → u(t) as h ↓ 0 and ih → t .
We now demonstrate that the above-mentioned theorem can be applied to the HIV infection model. To this end,
we ﬁx an mth stage of antiretroviral therapy and eliminate the sufﬁx m from the parameter, the associated rates and
coefﬁcients throughout the remainder of this section. We then recall the supply function
S(	) = S¯ − S∗	/(BS + 	) S¯, S∗ S¯,
the saturation functions
pk(	) = p∗k	/(ck + 	)p∗k for 	0 and k = 1, 2, 3, 4,
p5(	) = p∗5	/(c5 + 	)p∗5 for 	
; =0 for 	<
,
and the treatment functions
1(t) = exp(−d1t)1, 2(t) = max{exp(−d2t), d3}, t0,
Our mathematical model formulated in the previous section is a special case of (RDS) in the sense that  is a bounded
domain in R3 with smooth boundary and the unknown function u(t) = (u, vs, vr , ws, wr, uˆs, uˆr ) takes its values in
X = (Lp())7 with p> 3. We then deﬁne the three functionals 0,1,2 by
0(v) = IndD(v), D = (L∞+ ())7, 1(v) = ‖v1‖∞,
2(v) = max{‖u‖∞, ‖vs‖∞, ‖vr‖∞, ‖ws‖∞, ‖wr‖∞, ‖uˆs‖∞, ‖uˆr‖∞}
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for v = (u, vs, vr , ws, wr, uˆs, uˆr ) ∈ X. Then the domain D of admissible initial data introduced in (3) is given by
D = (L∞+ ())7.
Also, the bornologyB on D is deﬁned to be a family of subsets K of D such that K is bounded with respect to the three
functionals 0,1 and 2. In order to introduce a linear operator A representing the diffusion and advection, we deﬁne
Au = (1u,2vs,3vr ,4ws,5wr,6uˆs ,7uˆr ), (9)
where
1u = duu − vf · ∇u,
2vs = dvsvs − vf · ∇vs ,
3vs = dvrvr − vf · ∇vr ,
4ws = dwsws − vf · ∇ws ,
5wr = dwrwr − vf · ∇wr ,
6uˆs = duˆsuˆs − vf · ∇uˆs ,
7uˆr = duˆruˆr − vf · ∇uˆr
and the differential operator  is deﬁned in L∞() subject to the homogeneous Neumann boundary conditions:
u = (vs) = (vr ) = (ws) = (wr) = (uˆs) = (uˆr ) = 0
on ,  being the outward normal vector to .
Moreover, in order to formulate nonlinear operators B(t) describing the supply of CD4+T cells and interactions
with HIV virus, we deﬁne
B(t)u = (B1(t)u, B2(t)vs, B3(t)vr , B4(t)ws, B5(t)wr, B6(t)uˆs , B7(t)uˆr ), (10)
where each component of the seven dimensional vector represents the supply and reaction terms of the associated
governing equation in the model.
Let h> 0 be a time step size so that t may be approximated by t ∼ ih. Then the semi-implicit scheme (6) in our case
may be written as follows:
(I − h1)ui+1 = ui + h{Si − ui + p1i (ws,i + wr,i)ui − (1i (t)sws,i + rwr,i)ui
− (1i (t)∗s uˆs,i + ∗r uˆr,i )ui − (R,s + R,r )ui},
(I − h2)vs,i+1 = vs,i + h{1i (t)sws,iui − vs,i − p2i (ws,i + wr,i)vs,i + 1i (t)∗s uˆs,iui − R,svs,i},
(I − h3)vr,i+1 = vr,i + h{rwr,iui − vr,i − p2i (ws,i + wr,i)vr,i + ∗r uˆr,iui − R,rvr,i},
(I − h4)ws,i+1 = ws,i + h{(1 − )p3i (ws,i + wr,i)vs,i + 1i (t)∗s uˆs,iui
+ 2i (t)p5i (ws,i + wr,i)ws,i − ε(t)uiws,i − uiwr,i},
(I − h5)wr,i+1 = wr,i + h{p3i (ws,i + wr,i)vs,i + p4i (ws,i + wr,i)vr,i + ∗r uˆr,iwr,i
− ε(t)uiwr,i − uiwr,i},
(I − h6)uˆs,i+1 = uˆs,i + h{R,sui − ¯uˆs,i − 1i (t)act,s uˆs,i − p2i (ws,i + wr,i)act,s uˆs,i + R,svs,i},
(I − h7)u∗r,i+1 = uˆr,i + h{R,rui − ¯uˆr,i − p2i (ws,i + wr,i)act,r uˆr,i + R,rvr,i}.
For the above discrete scheme, we obtain the following result concerning the stability condition (GC).
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Lemma 3. Let h0 be a positive number such that 1/h0 is the maximum of the six numbers
+ (s + r )C2, + p∗2 + R,s, + p∗2 + R,r ,
(ε∗ + )C0, ¯+ act,s + act,sp∗2, ¯+ act,rp∗2 ,
where C2 is a positive constant speciﬁed in the proof below. Then for any > 0, h ∈ (0, h0) and any initial value
uh0 = v ∈ D there is K ∈ B such that the elements uhi generated through the scheme (6) all satisfy
uhi ∈ K for h ∈ (0, h0) and ih ∈ [0, ].
In particular, if uh0 = v0 in the sense that v ∈ (L∞+ ())7, then uhi 0 in the same sense.
Proof. We ﬁrst deﬁne three constants C0, C1 and C2 depending upon v,  and all the rates and coefﬁcients contained
in the model by
C0 = exp(p∗1)(1(vh0) + S0/p∗1),
C1 = max{+ p∗1 + (s + r + ∗s + ∗r )C0 + R,s + R,r ,
(s + ∗s )C0 + + p∗2 + R,s ,
(r + ∗r )C0 + + p∗2 + R,r ,
(1 − )p∗3 + (∗s + ε∗ + )C0 + ∗2p∗s , p∗3 + p∗4 + (∗r + ε∗ + )C0
R,s + ¯+ act,s + p∗2act,s + R,s, R,r + ¯+ p∗2act,r + R,r},
C2 = exp(C1)(1(xh0) + S0/C1).
Then, by an induction argument, we obtain the following estimates:
For h ∈ (0, h0) and i = 0, 1, . . . , Nh = [/h],
(i) |uhi |∞ = 1(uhi )(1 + hp∗1)i1(uh0) + hS0
i−1∑
j=0
(1 + hp∗1)j C0,
(ii) 2(uhi )(1 + hC1)i2(uh0) + hS0
i−1∑
j=0
(1 + hC1)j C2,
(iii) 0(uhi ) = 0, or, uhi , vhs,i , vhr,i , whs,i , whr,i , u∗hs,i , u∗hr,i0 .
These estimates together imply the desired assertion. 
Since A is dissipative in X and (I − hA)−1 is order-presenting, the above-mentioned estimates (i)–(iii) make it
possible to show that the operators A and B(t) satisfy the growth condition (H1) for B(t), the local Lipschitz condition
(H2) for B(t), the contractiveness condition (H3) for A and the quasidissipativity condition (H4) for A. Thus, we may
apply Theorem 2 to ﬁnd generalized solutions to the HIV infection process which satisfy the growth condition (GC).
In fact, it is seen from the recent result due to Nakamura [5] that the operator B(t) are one-sided G-differentiable on
D, and so that these generalized solutions become strong solutions provided that the initial data v lie in D(A) ∩ D.
Also, estimates similar to (i)–(iii) stated above can be obtained for semi-implicit ﬁnite-difference schemes con-
sistent with the evolution equation (EE) for the advection–diffusion operator A and reaction operator B(t) deﬁned
by (9) and (10).
4. Numerical simulations
A number of studies on the pathogenesis of HIV infection have been focused on peripheral blood mononuclear
cells so far. However, in this paper we focus our attention on the dynamics of host pathogen interactions with HIV1
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in mainly the lymphoid tissue. In this section some results of numerical simulations based on our HIV infection
model are presented together with some comments. The primary purpose of the numerical simulation is to analyze
changes in time of the levels of virus and states of disease progression, the rates of viral turnover, the relationship
between immune system activation and viral replication, and the time at which drug resistance start appearing by
mutation. The CD4+T cell count is understood to be the best indicator of the state of immunologic competence of
the patient with HIV infection. Our mathematical model of the dynamics of host pathogen interactions with HIV
virus encompasses a spectrum ranging from an acute syndrome associated with primary infection to a prolonged
asymptomatic state toward advanced disease. As mentioned in Section 1, lymphoid tissues are the major sites of the
establishment and propagation of HIV infection. Also, it should be noted that lymphocytes in the peripheral blood
represent only a few percent of the total body lymphocyte pool and so may not always accurately reﬂect the status
of the entire immune system. In order to choose appropriate initial data and a time interval, say [tm, tm+1], for the
evolution equation (EE) under the mth therapy, we referred to the aspect (explained also in Section 1) that the set point
of the level of steady state plasma viremia after approximately 1 year seems to correlate with the rapidity of disease
progression.
An attempt has been made to simulate the following four stages of the HIV infection process: the early and later
stages of HIV infection, themedian andmost crucial stage of disease progression after antiretroviral therapy has started,
and the last stage which suggests states in the case where all the treatments have been stopped.
We ﬁrst show how the solutions of our model look like in a parallelepiped domain. Since the computational domain
is 3D, the values of the governing equations may be shown by means of isosurfaces with colors indicating the amount
of population. We here take two governing equations for ws and wr . The yellow through brown colors show the
isosurfaces of the values ofwr , and the blue through red colors show the isosurfaces of the values ofws . Corresponding
to the four stages mentioned above, the four ﬁgures below illustrate the structure of the two solutions ws and wr .
Fig. 1 illustrates the primary stage after infection has been established. Treatment has not been started yet, and it
is observed that treatment-sensitive cells are much more proliﬁc than resistant cells. Fig. 2 shows the later stage of
infection. Treatment-resistant cells are still not as proliﬁc as sensitive cells. This eventually evolves into a stable state.
As mentioned in Section 2, it is inferred that mutation of sensitive virus occurs in this stage after the establishment
of chronic infection. Fig. 3 depicts a state after the ﬁrst antiretroviral therapy has been started. A stable state is
Fig. 1. Infection without treatment.
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Fig. 2. Later stage of infection.
Fig. 3. After antiretroviral therapy starts.
quickly reached, in which the resistant infected cells are comparatively dominant. The treatment seems to be effective
in the sense that it results in the almost complete destruction of sensitive virus, but this allows the resistant virus to
ﬂourish without competition with the immune system. Fig. 4 suggests a state after all the treatments have been stopped.
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Fig. 4. Treatment stops.
This result is obtained by means of the same model under the assumption that treatments are stopped at a speciﬁc
time step. Once treatments are stopped, resistant cells are still present and motivate rapid increase of drug-sensitive
cells. Thus it is likely to reach a state in which both types of cells coexist, and this may make further treatments less
effective. These results of our numerical simulations agree with medical and physiological aspects. We then present
our simulation results in Fig. 5 which consists of ﬁve graphs indicating the changes in time of the ﬁve parameters
u,ws,wr, vs and vr in that order. In each graph, the lower curve represents the change in time of the L1-norm (total
population) of the associated parameter and illustrates the infection process in the primary stage, the change in time of
disease progression under the ﬁrst antiretroviral therapy, and the last stage after all the therapies have been stopped. The
upper curve in each graph shows the change in time of the L∞-norm (maximum of the distributed population) of the
associated parameter. These L∞-curves may be useful for investigating not only stability of numerical computation,
but also tracing speciﬁc parts of the human body in which HIV virus are concentrated.
The ﬁrst part from Step 0 through Step 750 illustrates a period from the primary stage to the stage after infection
has been established. It is observed that treatment-sensitive cells are much more proliﬁc than drug-resistant cells.
Treatment-resistant cells are still not as proliﬁc as drug-sensitive cells. This eventually evolves into a comparatively
stable stage. As mentioned previously, it is expected that mutation of sensitive virus occurs on the next stage after the
establishment of chronic infection and application of antiretroviral therapy.
The second part of graph from Step 750 through Step 1500 depicts the change in time of disease progression which
takes place after the ﬁrst antiretroviral therapy has been started. A stable stage is quickly reached for each case. The
treatment seems to be effective in the sense that it results in the almost complete destruction of sensitive virus, although
this allows the resistant virus to ﬂourish without strong competition with the immune system.
The last part from Step 1500 through Step 2250 indicates a stage after all the treatments have been stopped. This
result is obtained by means of the same model under the assumption that treatment stops at a speciﬁc time. When
treatment stops, resistant virus are present and sensitive virus increase rapidly. Thus it is likely to reach a state in which
both types of cells coexist, and this may cause further treatment by some more effective therapy to be less effective.
These results of our numerical simulations agree with current medical and physiological aspects. In fact, the graphs
of the L1-norm of the ﬁve parameters u,ws,wr, vs and vr are similar to the numerical results presented in [3]. More
detailed and other important aspects will be discussed in the subsequent studies [6–8].
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Fig. 5. Simulation results.
It is best to regard HIV disease as the whole process from the beginning at the time of primary infection to progressing
through various stages. Active virus replication and progressive immunologic impairment occur throughout the course
ofHIV infection inmost patients. It should be our next plan to develop a newextendedmodel such that all of these aspects
are taken into account.
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